The completed SKNJCT-003 study is shaping Medicus Pharma’s next clinical strategy, with the 200 µg dose moving into an FDA-authorized Gorlin syndrome program while the company considers partnerships for nodular basal cell carcinoma.
Key Investor Takeaways
- Medicus Pharma (NASDAQ:MDCX) selected the 200 µg SkinJect patch as its proposed pivotal dose following the final analysis of its 90-patient Phase 2 SKNJCT-003 study.
- The company is applying the Phase 2 findings to SKNJCT-005, an FDA-authorized, NDA-enabling Phase 2b study in up to approximately 50 patients with Gorlin syndrome and multiple basal cell carcinomas.
- Future development will use a composite complete-response endpoint covering clinical and histological clearance, a later efficacy assessment and a non-penetrating sham comparator.
- Medicus intends to pursue strategic partnership opportunities for SkinJect in nodular basal cell carcinoma while concentrating its own clinical development on Gorlin syndrome.
- Applications for Orphan Drug Designation and Rare Pediatric Disease designation have been submitted to the FDA but have not yet been granted.
Why MDCX Stock Is in Focus
Medicus Pharma has published an abridged final Clinical Study Report for its Phase 2 SKNJCT-003 SkinJect study, identifying the 200 µg D-MNA patch as the proposed pivotal dose and defining several elements of its future clinical development strategy.
The randomized, double-blind study enrolled 90 patients across 10 U.S. sites, with all participants completing the trial without treatment discontinuations or withdrawals. Final efficacy analysis focused on patients with centrally confirmed nodular basal cell carcinoma.
Beyond dose selection, the findings prompted Medicus to adopt a composite complete-response endpoint combining clinical and histological clearance and to move the primary efficacy assessment to a later point based on continued improvement observed with longer follow-up.
The company also plans to replace the device-only microneedle comparator used in SKNJCT-003 with a non-penetrating sham comparator in future registrational development.
Why This Matters for Investors
The Phase 2 report gives Medicus a more defined clinical framework for SkinJect rather than simply providing another set of study results.
Most importantly, the findings have been incorporated into SKNJCT-005, the company’s FDA-authorized study in Gorlin syndrome. The trial is designed to enroll up to approximately 50 patients and evaluate the selected 200 µg SkinJect patch in patients with multiple BCC lesions.
Medicus believes a randomized, double-blind, sham-controlled design with approximately 90% statistical power could support discussions with the FDA regarding a potential single pivotal study approach. Whether that regulatory pathway is ultimately accepted remains subject to future FDA discussions.
The company’s development strategy also divides the SkinJect opportunity into two paths. Medicus plans to concentrate resources on the rare-disease Gorlin syndrome program while seeking a potential strategic partner to advance nodular BCC.
Medicus estimates around 11,000 U.S. Gorlin syndrome patients have active BCC, accounting for approximately 50,000 procedures annually. A company-commissioned commercial assessment modeled net pricing of approximately $25,800 per treatment, a $1.1 billion U.S. total addressable market and potential peak U.S. revenue of about $383 million. Those projections are non-risk-adjusted and depend on successful development, regulatory approval, reimbursement and commercial adoption.
What to Watch Next
The initiation and subsequent progress of SKNJCT-005 will be the main clinical development milestone following selection of the 200 µg dose.
Regulatory developments are also relevant. Medicus is awaiting decisions on its applications for Orphan Drug Designation and Rare Pediatric Disease designation, the latter of which could potentially provide eligibility for a Rare Pediatric Disease Priority Review Voucher if all applicable requirements are satisfied.
Investors can also watch for a potential SkinJect partnership in nodular BCC and whether the complete Phase 2 dataset is accepted for presentation at a scientific congress or publication in a peer-reviewed medical journal.